Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

R. T. Swords, J. Watts, H. P. Erba, J. K. Altman, M. Maris, F. Anwer, Z. Hua, H. Stein, H. Faessel, F. Sedarati, B. J. Dezube, F. J. Giles, B. C. Medeiros, D. J. DeAngelo

Research output: Contribution to journalLetter

16 Scopus citations
Original languageEnglish (US)
Article numbere520
JournalBlood cancer journal
Volume7
Issue number2
DOIs
StatePublished - Feb 3 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., Anwer, F., Hua, Z., Stein, H., Faessel, H., Sedarati, F., Dezube, B. J., Giles, F. J., Medeiros, B. C., & DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood cancer journal, 7(2), [e520]. https://doi.org/10.1038/bcj.2017.1